Description

Oxaliplatin Powder for Solution for Infusions 5 mg/ml. №1 Vial

Ingredients:

Each vial contains Oxaliplatin 100 mg as a lyophilized powder for reconstitution.

Dosage:

The recommended dosage of Oxaliplatin is 85 mg/m² administered as a 2-hour intravenous infusion every 2 weeks.

Indications:

Oxaliplatin is indicated for the treatment of advanced colorectal cancer. It is often used in combination with other chemotherapy medications.

Contraindications:

Do not use Oxaliplatin if you have a history of allergic reactions to platinum-containing compounds. It is also contraindicated in patients with pre-existing severe renal impairment.

Directions:

Oxaliplatin should only be administered by a healthcare professional experienced in chemotherapy infusion techniques. The solution should be prepared according to the manufacturer’s instructions and administered intravenously.

Scientific Evidence:

Studies have shown that Oxaliplatin, in combination with other chemotherapeutic agents, significantly improves progression-free survival and overall survival in patients with advanced colorectal cancer. Research published in the New England Journal of Medicine demonstrated the efficacy of Oxaliplatin-based regimens in the adjuvant treatment of colorectal cancer.

Additional Information:

Oxaliplatin may cause peripheral neuropathy, which can be dose-limiting. Patients should be monitored closely for signs of neuropathy during treatment. It is essential to follow proper safety protocols when handling and administering Oxaliplatin to minimize the risk of exposure.

Oxaliplatin exerts its pharmacological effects by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. This mechanism of action makes it an effective cytotoxic agent against rapidly dividing cancer cells.

Clinical trials have shown that Oxaliplatin is well-tolerated and has a manageable safety profile when used in appropriate doses and schedules. Compared to other platinum-based chemotherapies, Oxaliplatin has demonstrated comparable efficacy with a lower incidence of nephrotoxicity.